A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

AbstractObjectivesInvasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children  
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research

Related Links:

Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Discussion This case demonstrates successful cure of pre-B-ALL complicating XLA by alloSCT with restoration of B-cell development and functional antibody response. We are aware of only one previous case of pre-B-ALL in an XLA patient (21), which suggests that human BTK deficiency in itself does not predispose to pre-B-ALL. However, there are data to suggest that BTK may act as a tumor suppressor, and BTK deficiency may predispose to tumor development following a “second hit.” Mice with a genetic deficiency in Slp65, a gene encoding an adaptor protein that functions together with BTK, have a block in progenito...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsAny difference in price between PHiD-CV and PCV13 is expected to be the key driver of vaccine choice for preventing childhood pneumococcal disease in Turkey. At price parity, PHiD-CV use is likely to be a dominant strategy over the use of PCV13.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
CONCLUSION: The results from this study suggest that our NTHi AOM coinfection model is useful for assessing protein vaccines. PMID: 30136923 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research
Abstract BACKGROUND: Pneumococcal conjugate vaccines have potential to prevent significant proportion of childhood pneumonia. Finnish Invasive Pneumococcal disease vaccine trial was designed to assess the vaccine effectiveness (VE) of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against several outcomes. We now report results for pneumonia. METHODS: In this nationwide, cluster-randomised, double-blind trial, children younger than 19 months received PHiD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters. Infants younger than 7 months at the fir...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) have been successfully used in the Slovak national universal mass vaccination programme (UMV) to protect against invasive pneumococcal diseases (IPD), pneumonia and acute otitis media (AOM) since 2011. Six years after the introduction of PCV in paediatric UMV in Slovakia, we have estimated cost-effectiveness of the two vaccines.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Conclusions This model projected that PHiD-CV would provide both incremental health benefits and cost-savings compared with PCV-13 at price parity. Using PHiD-CV could result in substantial budget savings to the NHS. These savings could be used to implement other life-saving interventions.
Source: BMJ Open - Category: Journals (General) Authors: Tags: Open access, Global health, Health economics, Health policy, Infectious diseases, Paediatrics Research Source Type: research
Streptococcus pneumoniae commonly inhabits the nasopharynx as a member of the commensal biofilm. Infection with respiratory viruses, such as influenza A virus, induces commensal S. pneumoniae to disseminate beyond the nasopharynx and to elicit severe infections of the middle ears, lungs, and blood that are associated with high rates of morbidity and mortality. Current preventive strategies, including the polysaccharide conjugate vaccines, aim to eliminate asymptomatic carriage with vaccine-type pneumococci. However, this has resulted in serotype replacement with, so far, less fit pneumococcal strains, which has changed the...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Microbial Immunity and Vaccines Source Type: research
Abstract Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
The objective of this study is to estimate the potential effectiveness and cost-effectiveness of vaccinating infants with the pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) compared to the 13-valent pneumococcal conjugate vaccine (PCV-13) in Croatia. These vaccines are currently available only for risk groups and on private market with a limited uptake, representing less than 10% of annual birth cohort.
Source: Value in Health - Category: Global & Universal Authors: Source Type: research
More News: Children | Economics | Epidemiology | Haemophilus Influenzae (Hib) | Health Management | Influenza Vaccine | Meningitis Vaccine | New Zealand Health | Otitis | Otitis Media | Pfizer | Pneomococcal Vaccine | Pneumonia | Study | Vaccines